Sept 27 (Reuters) - Biohaven Pharmaceutical Holding Co Ltd
said on Monday its drug candidate, verdiperstat, failed
to show effectiveness in treating a rare neurological disorder
called multiple system atrophy.
Additional analyses are still pending and full-study results
will be presented at an upcoming scientific meeting, the
(Reporting by Manojna Maddipatla in Bengaluru; editing by